Practice Point 2.1.1:
Monitoring long-term glycemic control by HbA1c twice per year is reasonable for patients with diabetes. HbA1c may be measured as often as 4 times per year if the glycemic target is not met or after a change in antihyperglycemic therapy.

Practice Point 2.1.2:
Accuracy and precision of HbA1c measurement declines with advanced CKD (G4–G5), particularly among patients treated by dialysis, in whom HbA1c measurements have low reliability

Practice Point 2.1.4:
Daily glycemic monitoring with CGM or self-monitoring of blood glucose (SMBG) may help prevent hypoglycemia and improve glycemic control when antihyperglycemic therapies associated with risk of hypoglycaemia are used.

Practice Point 2.1.5:
For patients with type 2 diabetes (T2D) and CKD who choose not to do daily glycemic monitoring by CGM or SMBG, antihyperglycemic agents that pose a lower risk of hypoglycemia are preferred and should be administered in doses that are appropriate for the level of eGFR

Practice Point 2.1.3:
A glucose management indicator (GMI) derived from continuous glucose monitoring (CGM) data can be used to index glycemia for individuals in whom HbA1c is not concordant with directly measured blood glucose levels or clinical symptoms.